Document Detail


Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion.
MedLine Citation:
PMID:  11090479     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To study the effect of superselective ophthalmic artery fibrinolysis as a treatment for central retinal vein occlusion (CRVO). METHODS: Retrospective, university based single centre study. The charts of 26 eyes of 26 patients treated were reviewed. Among the 26 patients, there were nine cases of combined artery and vein occlusion, three cases of combined cilioretinal artery and CRVO, and 14 cases of classic CRVO. Complete preoperative and postoperative ophthalmological examination and fluorescein angiography were performed in all cases. The therapeutic procedure comprised the infusion of urokinase through a microcatheter into the ostium of the ophthalmic artery, via a femoral artery approach. The main outcome measure was the improvement in visual acuity 48 hours after the procedure. RESULTS: Six eyes of six patients exhibited significant improvement in visual acuity immediately after the fibrinolysis procedure. Among them, four had a initial funduscopic appearance suggestive of combined occlusion of the central retinal artery (CRAO) and vein. For these patients, the visual benefit was maintained in the long term. Intravitreal haemorrhage occurred in two patients. There were no extraocular complications linked to the procedure. CONCLUSIONS: Selective ophthalmic artery infusion of urokinase was followed by improvement in VA in six out of 26 cases of CRVO. Eyes with combined CRAO and CRVO with recent visual loss appeared to be the most responsive. This treatment did not prevent the occurrence of ischaemia in the failure cases. The efficacy of in situ fibrinolysis for treatment of CRVO needs to be further evaluated in a controlled study.
Authors:
M Paques; J N Vallée; D Herbreteau; A Aymart; P Y Santiago; F Campinchi-Tardy; D Payen; J J Merlan; A Gaudric; P Massin
Related Documents :
3566029 - Optic neuropathy and central retinal artery occlusion in a case of herpes zoster ophtha...
10320159 - Retinal artery air embolism in dogs: fluorescein angiographic evaluation of effects of ...
11847449 - Development and modelling of arterial applanation tonometry: a review.
10926989 - Optic disk and retinal nerve fiber layer damage after transient central retinal artery ...
15926729 - Supraorbital craniotomy for parasellar lesions. technical note.
15623139 - Branch retinal artery occlusion following embolization of a maxillary sinus tumor.
10515489 - Anterior thalamoperforating artery aneurysm associated with internal carotid artery occ...
10667509 - Evolution of lactate/pyruvate and arterial ketone body ratios in the early course of ca...
12084889 - Sudden coma from acute bilateral internal carotid artery territory infarction.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The British journal of ophthalmology     Volume:  84     ISSN:  0007-1161     ISO Abbreviation:  Br J Ophthalmol     Publication Date:  2000 Dec 
Date Detail:
Created Date:  2000-12-13     Completed Date:  2001-01-04     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0421041     Medline TA:  Br J Ophthalmol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1387-91     Citation Subset:  IM    
Affiliation:
Department of Ophthalmology, Hôpital Lariboisière, Université Paris 7, Paris, France. michel.paques@lrb.ap-hop-paris.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Female
Fundus Oculi
Humans
Infusions, Intra-Arterial
Male
Middle Aged
Ophthalmic Artery
Pilot Projects
Plasminogen Activators / administration & dosage,  therapeutic use*
Retinal Artery Occlusion / drug therapy
Retinal Vein Occlusion / drug therapy*
Retrospective Studies
Thrombolytic Therapy / methods*
Treatment Outcome
Urokinase-Type Plasminogen Activator / administration & dosage,  therapeutic use*
Visual Acuity / drug effects
Chemical
Reg. No./Substance:
EC 3.4.21.-/Plasminogen Activators; EC 3.4.21.73/Urokinase-Type Plasminogen Activator
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diode laser treatment of posterior retinopathy of prematurity.
Next Document:  Macular circulation in patients with diabetes mellitus with and without arterial hypertension.